AlveoGene, an Oxford, UK-based innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy, launched in conjunction with seed funding.
The amount of the deal was not disclosed.
Backers included Oxford Science Enterprises, Harrington Discovery Institute at University Hospitals, Old College Capital, and the University of Edinburgh’s venture investment fund.
Created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC), AlveoGene is a new gene therapy company that initially aims to leverage proprietary lentiviral gene therapy platform designed and developed by GTC specifically for inhaled delivery. First target indication is alpha-1 antitrypsin deficiency disease (AATD), a degenerative condition that can lead to early onset emphysema
David Hipkiss, an experienced life sciences company builder and leader, was appointed as Executive Chair.
FinSMEs
14/09/2023